Skip to main content

Table 5 Survival analysis with progression-free survival in total cohort and in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (n = 93)

From: Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma

Clinicopathologic variables

Total cohort

Patients treated with R-CHOP

Univariate

Multivariate

Univariate

Multivariate

p value

p value

HR (95% CI)

p value

p value

HR (95% CI)

Age

 > 60 vs. ≤ 60

0.035

0.181

 

0.074

  

Sex

 Male vs. female

0.544

  

0.661

  

ECOG PS

 ≥ 2 vs. < 2

<0.001

0.010

3.717 (1.371–10.080)

< 0.001

0.031

3.286 (1.116–9.677)

B symptoms

 Present vs. absent

0.049

0.807

 

0.112

  

Serum LDH

 Elevated vs. normal

0.003

0.328

 

0.033

0.319

 

IPI

 3–5 vs. 0–2

< 0.001

0.001

4.910 (1.888–12.767)

< 0.001

0.002

4.823 (1.763–13.191)

Primary site

 Extranodal vs. nodal

0.488

  

0.523

  

Extranodal site

 ≥ 2 vs. < 2

< 0.001

0.649

 

0.001

0.978

 

Bone marrow involvement

 Present vs. absent

0.308

  

0.359

  

Bulky mass

 ≥ 10 cm vs. < 10 cm

0.136

  

0.048

0.010

4.664 (1.449–15.017)

Ann Arbor stage

 III–IV vs. I–II

< 0.001

0.682

 

< 0.001

0.812

 

Hans classification

 Non-GCB vs. GCB

0.075

  

0.135

  

Treatment regimen

 RCHOP vs. other

0.676

  

–

  

BCL2 expression

 Positive vs. negative

0.391

  

0.699

  

BCL6 expression

 Positive vs. negative

0.247

  

0.545

  

CD10 expression

 Positive vs. negative

0.543

  

0.778

  

MUM1 expression

 Positive vs. negative

0.138

  

0.211

  

PD-L1 tumor cell expression

 Positive vs. negative

0.400

  

0.353

  

PD-L1 immune cell expression

 Positive vs. negative

0.187

  

0.146

  

PD-L1 gene alteration

 Present vs. absent

0.900

  

0.871

  

pSTAT3 expression (> 40%)

 Positive vs. negative

0.021

0.017

2.724 (1.196–6.204)

0.015

0.007

3.510 (1.418–8.692)

  1. PD-L1: programmed cell death-ligand 1; pSTAT3: phosphorylated signal transducer and activator of transcription 3; ECOG PS: the Eastern Cooperative Group Performance Status; GCB: germinal center B-cell like; R-CHOP: rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone